Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond P Baumann

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Biotechniques|May 22, 2002
Novel selection marker for mammalian cell transfectionRaymond P Baumann, David H Sherman, Alan C Sartorelli
Molecules (Basel, Switzerland)|January 9, 2021
Design Strategy for the EPR Tumor-Targeting of 1,2-Bis(sulfonyl)-1-alkylhydrazinesPhilip G Penketh, Hugh S Williamson, Raymond P Baumann, et al.
Journal of Medicinal Chemistry|January 15, 2013
Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanineRui Zhu, Raymond P Baumann, Philip G Penketh, et al.
Oncology Research|January 18, 2006
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activationRaymond P Baumann, Helen A Seow, Krishnamurthy Shyam, et al.
Radiation Research|October 31, 2008
Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cellsRaymond P Baumann, Philip G Penketh, Helen A Seow, et al.
Biochemical Pharmacology|March 15, 2011
KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cellsRaymond P Baumann, Kimiko Ishiguro, Philip G Penketh, et al.
Chemical Research in Toxicology|March 13, 2014
Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119WPhilip G Penketh, Krishnamurthy Shyam, Rui Zhu, et al.
Leukemia Research|May 16, 2008
Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating speciesPhilip G Penketh, Raymond P Baumann, Kimiko Ishiguro, et al.
Biochemical Pharmacology|July 27, 2010
Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferaseKimiko Ishiguro, Yong-Lian Zhu, Krishnamurthy Shyam, et al.
Chemical Biology & Drug Design|June 22, 2017
pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugsPhilip G Penketh, Richard A Finch, Rachel Sauro, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Biotechniques|May 22, 2002
Novel selection marker for mammalian cell transfectionRaymond P Baumann, David H Sherman, Alan C Sartorelli
Molecules (Basel, Switzerland)|January 9, 2021
Design Strategy for the EPR Tumor-Targeting of 1,2-Bis(sulfonyl)-1-alkylhydrazinesPhilip G Penketh, Hugh S Williamson, Raymond P Baumann, et al.
Journal of Medicinal Chemistry|January 15, 2013
Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanineRui Zhu, Raymond P Baumann, Philip G Penketh, et al.
Oncology Research|January 18, 2006
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activationRaymond P Baumann, Helen A Seow, Krishnamurthy Shyam, et al.
Radiation Research|October 31, 2008
Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cellsRaymond P Baumann, Philip G Penketh, Helen A Seow, et al.
Biochemical Pharmacology|March 15, 2011
KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cellsRaymond P Baumann, Kimiko Ishiguro, Philip G Penketh, et al.
Chemical Research in Toxicology|March 13, 2014
Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119WPhilip G Penketh, Krishnamurthy Shyam, Rui Zhu, et al.
Leukemia Research|May 16, 2008
Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating speciesPhilip G Penketh, Raymond P Baumann, Kimiko Ishiguro, et al.
Biochemical Pharmacology|July 27, 2010
Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferaseKimiko Ishiguro, Yong-Lian Zhu, Krishnamurthy Shyam, et al.
Chemical Biology & Drug Design|June 22, 2017
pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugsPhilip G Penketh, Richard A Finch, Rachel Sauro, et al.
Pageof 3